Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096024 · ClinicalTrials.gov registry record
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
A clinical trial of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- 1,772
- Enrollment target
- 1
- Study location
NCT07096024 is a study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 1,772 participants, above the 551-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (222% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07096024, a study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,772 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to: * compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the market) * look into the factors that can cause ILD in new users of palbociclib. This study uses patient data without giving out any personal information of the patient. This data is taken from a hospital-based claims database of the MDV database, that includes data from more than 400 hospitals in Japan. This study will use data of patients who are: * diagnosed with breast cancer that include newly treated with palbociclib and/or other endocrine-based therapies for inoperable or recurrent breast cancer between 25 November 2011 and 30 November 2024.
Conditions Studied
Interventions
- DRUG fulvestrant
- DRUG palbociclib plus fulvestrant
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,772 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2025-02-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07096024
The ClinicalTrials.gov registry entry for NCT07096024 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,772 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 551-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (222% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which fulvestrant is the first listed.
NCT07096024 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07096024 about?
NCT07096024 is a clinical study titled "A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market". The purpose of the study is to: * compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the market) * look into the factors that can cause ILD in new users of palbo...
What is the current status of trial NCT07096024?
This trial is currently completed. The enrollment target is 1,772 participants. The study started on 2025-01-21. Estimated completion is 2025-02-07.
What conditions does trial NCT07096024 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT07096024?
The interventions under investigation include: fulvestrant (DRUG), palbociclib plus fulvestrant (DRUG).
Who is sponsoring clinical trial NCT07096024?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096024 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Registry Study of Breast Microseed Treatment
RECRUITING
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.